# A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

> **NCT06741982** · PHASE1 · RECRUITING · sponsor: **West China Hospital** · enrollment: 21 (estimated)

## Conditions studied

- HNSCC
- Lysogenic HSV Virus
- Neoadjuvant Therapy
- Immunotherapy
- Targeted Therapy

## Interventions

- **BIOLOGICAL:** Lysogenic HSV virus.
- **DRUG:** Tislelizumab
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT06741982
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2026-12-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06741982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06741982, "A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06741982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*